Ray Dalio's AZN Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 462,859 shares of AstraZeneca PLC (AZN) worth $35.51 M, representing 0.14% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 18 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in AZN, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 468,353 shares. Largest reduction occurred in Q3 2025, reducing 158,045 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's AstraZeneca PLC (AZN) Holding Value Over Time
Track share changes against reported price movement
Quarterly AstraZeneca PLC (AZN) Trades by Ray Dalio
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2021 | +91,336 | New Buy | 91,336 | $59.90 |
| Q3 2021 | +12,897 | Add 14.12% | 104,233 | $60.06 |
| Q4 2021 | -31,341 | Reduce 30.07% | 72,892 | $58.25 |
| Q1 2022 | +3,694 | Add 5.07% | 76,586 | $66.34 |
| Q2 2022 | -5,584 | Reduce 7.29% | 71,002 | $66.07 |
| Q3 2022 | +8,789 | Add 12.38% | 79,791 | $54.84 |
| Q4 2022 | +9,827 | Add 12.32% | 89,618 | $67.80 |
| Q1 2023 | +7,994 | Add 8.92% | 97,612 | $69.41 |
| Q2 2023 | +12,149 | Add 12.45% | 109,761 | $71.57 |
| Q3 2023 | +4,048 | Add 3.69% | 113,809 | $67.72 |
| Q4 2023 | +46,241 | Add 40.63% | 160,050 | $67.35 |
| Q1 2024 | -60,788 | Reduce 37.98% | 99,262 | $67.75 |
| Q2 2024 | +109,915 | Add 110.73% | 209,177 | $77.99 |
| Q3 2024 | -4,069 | Reduce 1.95% | 205,108 | $77.91 |
| Q4 2024 | +468,353 | Add 228.34% | 673,461 | $65.52 |
| Q1 2025 | +17,639 | Add 2.62% | 691,100 | $73.50 |
| Q2 2025 | -70,196 | Reduce 10.16% | 620,904 | $69.88 |
| Q3 2025 | -158,045 | Reduce 25.45% | 462,859 | $76.72 |
Ray Dalio's AstraZeneca PLC Investment FAQs
Ray Dalio first purchased AstraZeneca PLC (AZN) in Q2 2021, acquiring 91,336 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held AstraZeneca PLC (AZN) for 18 quarters since Q2 2021. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's largest addition to AstraZeneca PLC (AZN) was in Q4 2024, adding 673,461 shares worth $44.13 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 462,859 shares of AstraZeneca PLC (AZN), valued at approximately $35.51 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, AstraZeneca PLC (AZN) represents approximately 0.14% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's peak holding in AstraZeneca PLC (AZN) was 691,100 shares, as reported at the end of Q1 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.